NasdaqGM - Nasdaq Real Time Price USD

Altimmune, Inc. (ALT)

Compare

9.03

+0.44

(+5.12%)

At close: December 13 at 4:00:02 PM EST

8.92

-0.11

(-1.22%)

After hours: 7:52:36 PM EST

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders i

GlobeNewswire 11 days ago

ALT
+5.12%
Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Annual Evercore HealthCONx Conference (Coral Gables, FL)Tuesday, December 3, 2024Fireside Chat at 10:50 a.m. Eastern Time Piper Sandler Annual Healthcare Conference (New York, NY)Wednesday, December 4, 2024Fireside Chat

GlobeNewswire 17 days ago

ALT
+5.12%
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (G

GlobeNewswire 28 days ago

ALT
+5.12%
Altimmune Third Quarter 2024 Earnings: Beats Expectations

Altimmune ( NASDAQ:ALT ) Third Quarter 2024 Results Key Financial Results Net loss: US$22.8m (loss widened by 11% from...

Simply Wall St. 29 days ago

ALT
+5.12%
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, Novembe

GlobeNewswire last month

ALT
+5.12%
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including SEC reporting and investor relations. “We are pleased to welcome Greg to Altimmune’s executive team during such a pivotal time in our evolution. He has a wealth of experience that we believ

GlobeNewswire last month

ATAI

ALT
+5.12%
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to employ Gregory Weaver as Altimmune’s Chief Financial Officer effective November 11, 2024. The equity awards were approved on November 6, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Weav

GlobeNewswire last month

ALT
+5.12%
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and potential benefits of balanced GLP-1/glucagon dual agonism GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) and

GlobeNewswire last month

ALT
+5.12%
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at htt

GlobeNewswire last month

ALT
+5.12%
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD) in San Diego, CA taking place November 15-19, 2024. The data were derived from Altimmun

GlobeNewswire last month

ALT
+5.12%
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference: Conference:H.C. Wainwright 8thAnnual MASH Virtual Conference Presenters:Vipin Garg, Ph.D., Chief Executive Officer Scott Harris, M.D., Chief Medical Officer Date

GlobeNewswire 2 months ago

ALT
+5.12%
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program with U.S. Food and Drug Administration (FDA) has been scheduled for early November 2024 Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning in Q4 2024 GAITHERSBURG, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (N

GlobeNewswire 2 months ago

ALT
+5.12%
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose tissue (VAT) at Week 48 has been corrected from 25.6% to 28.3% and the reduction of subcutaneous adipose tissue has been corrected from 20.1% to 19.5%. The revised release follows: Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation i

GlobeNewswire 3 months ago

ALT
+5.12%
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from its Phase 2, MRI-based bod

GlobeNewswire 3 months ago

ALT
+5.12%
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the

GlobeNewswire 3 months ago

ALT
+5.12%
Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags

Altimmune ( NASDAQ:ALT ) First Half 2024 Results Key Financial Results Net loss: US$49.0m (loss widened by 36% from 1H...

Simply Wall St. 4 months ago

ALT
+5.12%
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune

GlobeNewswire 4 months ago

ALT
+5.12%
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024. CytoSorbents’ management will host a live conference call, presentation webcast, and a question and answer session starting at 4:30PM EDT the same day. Webcast De

GlobeNewswire 4 months ago

CTSO

ALT
+5.12%
With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies Altimmune's stock price is sensitive to their trading...

Simply Wall St. 4 months ago

ALT
+5.12%
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https:/

GlobeNewswire 4 months ago

ALT
+5.12%

Performance Overview

Return	ALT	S&P 500
YTD	-19.73%	+26.86%
1-Year	+52.02%	+30.31%
3-Year	-4.14%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Altimmune, Inc. (ALT)

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Performance Overview